Q3138683 (Q3138683): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Objectives: 1.- Analyse, in patients with DM2, the association of serum FGF21 concentrations and other parameters of lipid and glycid metabolism, with: a) subclinical myocardial dysfunction, b) ectopic fat deposits (cardiac and hepatic), c) clinical prognosis in patients with chronic heart failure (CI), d) presence/absence non-alcoholic steatohepatitis, e) dietary intake pattern, f) glycemic control optimisation. 2.- Study, in animal models of i...) |
||||||||||||||
| Property / summary | |||||||||||||||
Objectives: 1.- Analyse, in patients with DM2, the association of serum FGF21 concentrations and other parameters of lipid and glycid metabolism, with: a) subclinical myocardial dysfunction, b) ectopic fat deposits (cardiac and hepatic), c) clinical prognosis in patients with chronic heart failure (CI), d) presence/absence non-alcoholic steatohepatitis, e) dietary intake pattern, f) glycemic control optimisation. 2.- Study, in animal models of insulin resistance and DM2, the association of FGF21 with the accumulation of lipids in myocardium, structure and cardiac lipotoxicity. 3.- Study, in cardiomyocytes (HL-1) and in hepatocytes (HepG2), the intracellular signaling pathway of FGF21 under conditions that mimic DM2 4.- Analyse, in HL-1 cardiomyocytes, the effect of HepG2 secretoma on FGF-21 signaling pathway under DM2 conditions. Methods: 1) 300 patients with DM2 without HF or CV events: a) cardiac and hepatic ultrasound, clinical and glycid and lipid metabolism variables, FGF21, modified LDL, HF biomarkers, steatosis and hepatic fibrosis indexes, d) serological steatohepatitis test (n=60), e) food frequency questionnaire, b) 20 patients with and 20 patients without myocardial dysfunction: Cardiac and hepatic MRI with spectroscopy, c) 400 patients with clinical HF: clinical and lipid and glycid metabolism variables, and f) 20 newly diagnosed DM2 patients with poor glycemic control (HbA1c>8 %) assessed before and 1 year after glycemic optimisation, 2) animal models: db/+ mice with a diet rich in fat, mouse db/db. 3) Cardiomyocytes (HL-1) and hepatocytes (HepG2): exposure to recombinant FGF21 in the presence/absence of high levels of glucose, insulin and fatty acids, abundance of phosphorylated ERK, mRNA of ß-klotho. (English) | |||||||||||||||
| Property / summary: Objectives: 1.- Analyse, in patients with DM2, the association of serum FGF21 concentrations and other parameters of lipid and glycid metabolism, with: a) subclinical myocardial dysfunction, b) ectopic fat deposits (cardiac and hepatic), c) clinical prognosis in patients with chronic heart failure (CI), d) presence/absence non-alcoholic steatohepatitis, e) dietary intake pattern, f) glycemic control optimisation. 2.- Study, in animal models of insulin resistance and DM2, the association of FGF21 with the accumulation of lipids in myocardium, structure and cardiac lipotoxicity. 3.- Study, in cardiomyocytes (HL-1) and in hepatocytes (HepG2), the intracellular signaling pathway of FGF21 under conditions that mimic DM2 4.- Analyse, in HL-1 cardiomyocytes, the effect of HepG2 secretoma on FGF-21 signaling pathway under DM2 conditions. Methods: 1) 300 patients with DM2 without HF or CV events: a) cardiac and hepatic ultrasound, clinical and glycid and lipid metabolism variables, FGF21, modified LDL, HF biomarkers, steatosis and hepatic fibrosis indexes, d) serological steatohepatitis test (n=60), e) food frequency questionnaire, b) 20 patients with and 20 patients without myocardial dysfunction: Cardiac and hepatic MRI with spectroscopy, c) 400 patients with clinical HF: clinical and lipid and glycid metabolism variables, and f) 20 newly diagnosed DM2 patients with poor glycemic control (HbA1c>8 %) assessed before and 1 year after glycemic optimisation, 2) animal models: db/+ mice with a diet rich in fat, mouse db/db. 3) Cardiomyocytes (HL-1) and hepatocytes (HepG2): exposure to recombinant FGF21 in the presence/absence of high levels of glucose, insulin and fatty acids, abundance of phosphorylated ERK, mRNA of ß-klotho. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Objectives: 1.- Analyse, in patients with DM2, the association of serum FGF21 concentrations and other parameters of lipid and glycid metabolism, with: a) subclinical myocardial dysfunction, b) ectopic fat deposits (cardiac and hepatic), c) clinical prognosis in patients with chronic heart failure (CI), d) presence/absence non-alcoholic steatohepatitis, e) dietary intake pattern, f) glycemic control optimisation. 2.- Study, in animal models of insulin resistance and DM2, the association of FGF21 with the accumulation of lipids in myocardium, structure and cardiac lipotoxicity. 3.- Study, in cardiomyocytes (HL-1) and in hepatocytes (HepG2), the intracellular signaling pathway of FGF21 under conditions that mimic DM2 4.- Analyse, in HL-1 cardiomyocytes, the effect of HepG2 secretoma on FGF-21 signaling pathway under DM2 conditions. Methods: 1) 300 patients with DM2 without HF or CV events: a) cardiac and hepatic ultrasound, clinical and glycid and lipid metabolism variables, FGF21, modified LDL, HF biomarkers, steatosis and hepatic fibrosis indexes, d) serological steatohepatitis test (n=60), e) food frequency questionnaire, b) 20 patients with and 20 patients without myocardial dysfunction: Cardiac and hepatic MRI with spectroscopy, c) 400 patients with clinical HF: clinical and lipid and glycid metabolism variables, and f) 20 newly diagnosed DM2 patients with poor glycemic control (HbA1c>8 %) assessed before and 1 year after glycemic optimisation, 2) animal models: db/+ mice with a diet rich in fat, mouse db/db. 3) Cardiomyocytes (HL-1) and hepatocytes (HepG2): exposure to recombinant FGF21 in the presence/absence of high levels of glucose, insulin and fatty acids, abundance of phosphorylated ERK, mRNA of ß-klotho. (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 13:03, 12 October 2021
Project Q3138683 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3138683 in Spain |
Statements
67,000.0 Euro
0 references
134,000.0 Euro
0 references
50.0 percent
0 references
1 January 2018
0 references
31 March 2021
0 references
FUNDACION INSTITUTO DE INVESTIGACION EN CIENCIAS DE LA SALUD GERMANS TRIAS I PUJOL
0 references
41°26'57.66"N, 2°14'53.70"E
0 references
08015
0 references
Objetivos: 1.- Analizar, en pacientes con DM2, la asociación de las concentraciones séricas de FGF21 y de otros parámetros del metabolismo lipídico y glucídico, con: a) disfunción miocárdica subclínica, b) depósito ectópico de grasa (cardíaca y hepática), c) pronóstico clínico en pacientes con insuficiencia cardíaca (IC) crónica, d) presencia/ausencia esteatohepatitis no alcohólica, e) patrón ingesta alimentaria, f) optimitzación del control glucémico. 2.- Estudiar, en modelos animales de resistencia a la insulina y de DM2, la asociación de FGF21 con el acúmulo de lípidos en miocardio, estructura y lipotoxicidad cardíaca. 3.- Estudiar, en cardiomiocitos (HL-1) y en hepatocitos (HepG2) la vía de señalización intracelular de FGF21 en condiciones que mimeticen la DM2 4.- Analizar, en cardiomiocitos HL-1, el efecto del secretoma HepG2 sobre la via de señalización de FGF-21 en condiciones de DM2. Métodos: 1) 300 pacientes con DM2 sin IC ni eventos CV: a) ecografía cardíaca y hepática, variables clínicas y del metabolismo glucídico y lipídico, FGF21, LDL modificadas, biomarcadores de IC, índices de esteatosis y fibrosis hepática, d) test serológico esteatohepatitis (n=60), e) cuestionario frecuencia alimentaria, b) 20 pacientes con y 20 sin disfunción miocárdica: RMN cardíaca y hepática con espectroscopia, c) 400 pacientes con IC clínica: variables clínicas y del metabolismo lipídico y glucídico, y f) 20 pacientes DM2 de recién diagnóstico con mal control glucémico (HbA1c>8%) valorados antes y 1 año después de su optimización glucémica, 2) modelos animales: ratones db/+ con una dieta rica en grasas, ratón db/db. 3) Cardiomiocitos (HL-1) y hepatocitos (HepG2): exposición a FGF21 recombinante en presencia/ausencia de niveles elevados de glucosa, insulina y ácidos grasos, abundancia de ERK fosforilada, mRNA de ß-klotho. (Spanish)
0 references
Objectives: 1.- Analyse, in patients with DM2, the association of serum FGF21 concentrations and other parameters of lipid and glycid metabolism, with: a) subclinical myocardial dysfunction, b) ectopic fat deposits (cardiac and hepatic), c) clinical prognosis in patients with chronic heart failure (CI), d) presence/absence non-alcoholic steatohepatitis, e) dietary intake pattern, f) glycemic control optimisation. 2.- Study, in animal models of insulin resistance and DM2, the association of FGF21 with the accumulation of lipids in myocardium, structure and cardiac lipotoxicity. 3.- Study, in cardiomyocytes (HL-1) and in hepatocytes (HepG2), the intracellular signaling pathway of FGF21 under conditions that mimic DM2 4.- Analyse, in HL-1 cardiomyocytes, the effect of HepG2 secretoma on FGF-21 signaling pathway under DM2 conditions. Methods: 1) 300 patients with DM2 without HF or CV events: a) cardiac and hepatic ultrasound, clinical and glycid and lipid metabolism variables, FGF21, modified LDL, HF biomarkers, steatosis and hepatic fibrosis indexes, d) serological steatohepatitis test (n=60), e) food frequency questionnaire, b) 20 patients with and 20 patients without myocardial dysfunction: Cardiac and hepatic MRI with spectroscopy, c) 400 patients with clinical HF: clinical and lipid and glycid metabolism variables, and f) 20 newly diagnosed DM2 patients with poor glycemic control (HbA1c>8 %) assessed before and 1 year after glycemic optimisation, 2) animal models: db/+ mice with a diet rich in fat, mouse db/db. 3) Cardiomyocytes (HL-1) and hepatocytes (HepG2): exposure to recombinant FGF21 in the presence/absence of high levels of glucose, insulin and fatty acids, abundance of phosphorylated ERK, mRNA of ß-klotho. (English)
12 October 2021
0 references
Badalona
0 references
Identifiers
PI17_01362
0 references